Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04126083
Other study ID # 19-0002763
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date September 1, 2019
Est. completion date April 15, 2021

Study information

Verified date January 2022
Source Mayo Clinic
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary objective is to investigate the effects of lofexidine in adults undergoing opioid tapering prior to elective lumbar spine surgery.


Description:

In this clinical trial, an open label design will be used to facilitate opioid tapering during a 12-day period prior to elective spine surgery. The primary outcome measure of this study is the number of patients who achieve a 50% reduction in daily opioid dose at day 12.


Recruitment information / eligibility

Status Completed
Enrollment 6
Est. completion date April 15, 2021
Est. primary completion date April 15, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: 1. Age 18 to 70 years. 2. Chronic lumbar spine pain for = 3 months duration. 3. Scheduled for elective lumbar spine surgery. 4. Daily morphine equivalent dose between 50 mg and 200 mg. Exclusion Criteria: 1. Cancer-related pain. 2. Medical or surgical conditions that could be adversely impacted by opioid tapering or use of lofexidine including, but not exclusively limited to, cardiac disease, inflammatory bowel disease, renal or hepatic impairment, vascular disease, and history of anaphylaxis. Patients may be excluded for other comorbid medical or surgical conditions based on the physician investigator's discretion. 3. History of schizophrenia or other chronic psychiatric disorder that could be adversely impacted by opioid tapering or use of lofexidine. Patients may be excluded for other comorbid mental health conditions based on the physician investigator's discretion. 4. Neurological condition that impair functioning in an ambulatory setting or could be adversely impacted by opioid tapering or use of lofexidine including, but not exclusively limited to, Parkinson's disease, amyotrophic lateral sclerosis, or a dementing illness. Patients may be excluded for other neurological conditions based on the physician investigator's discretion. 5. Active substance abuse disorder. 6. Inability to function in an ambulatory care setting due to severe deconditioning requiring use of supportive gait aids including a cane or walker. Patients may be excluded for other functional problems based on the physician investigator's discretion. 7. History of adverse effects attributed to opioid tapering or lofexidine use. 8. Use of medications from drug classes known to have adverse interactions with lofexidine including, but not exclusively limited to, beta-blockers, calcium channel blockers, alpha 1 and 2 receptor antagonists, tricyclic antidepressants, benzodiazepines, and selective serotonin reuptake inhibitors. Patients may be excluded for use of other medications based on the physician investigator's and research pharmacy's discretion.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Lofexidine Oral Tablet
lofexidine 0.54 mg 4 times daily

Locations

Country Name City State
United States Mayo Clinic in Rochester Rochester Minnesota

Sponsors (2)

Lead Sponsor Collaborator
Mayo Clinic USWM, LLC (dba US WorldMeds)

Country where clinical trial is conducted

United States, 

References & Publications (1)

Fishman M, Tirado C, Alam D, Gullo K, Clinch T, Gorodetzky CW; CLEEN-SLATE Team. Safety and Efficacy of Lofexidine for Medically Managed Opioid Withdrawal: A Randomized Controlled Clinical Trial. J Addict Med. 2019 May/Jun;13(3):169-176. doi: 10.1097/ADM.0000000000000474. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Opioid Tapering The number of patients who achieve a 50% reduction in daily opioid dose at day 12. 12 days
See also
  Status Clinical Trial Phase
Completed NCT04080037 - Assessing Opioid Care Practices Using CPV Patient Simulation Modules N/A
Completed NCT04140955 - Opioid Tapering After Spine Surgery N/A
Not yet recruiting NCT03813095 - Exploratory Dose Ranging Study Assessing APH-1501 for the Treatment of Opioid Addiction Phase 2
Completed NCT01262092 - Effects of Gabapentin Versus Placebo on Buprenorphine Detoxification of Opioid-dependent Individuals Phase 2
Completed NCT04075214 - Transcutaneous Auricular Neurostimulation (tAN) for Symptoms of Opioid Withdrawal N/A
Recruiting NCT04325659 - An Innovative Intervention for OUD Treatment Phase 2/Phase 3
Withdrawn NCT03678792 - Comparison of Three Opioid Detoxification Treatment Regimens Phase 3
Terminated NCT04162145 - BRIDGE Device for Treatment of Opioid Withdrawal N/A
Completed NCT04238754 - Oral Cannabidiol for Opioid Withdrawal Phase 1/Phase 2
Recruiting NCT05053503 - Delivering Transcutaneous Auricular Neurostimulation to Improve Relapse Prevention in Opioid Use Disorder N/A
Recruiting NCT05555485 - Understanding the Effects of Transcutaneous Auricular Neurostimulation for Treatment of Chronic Pain N/A
Active, not recruiting NCT03485430 - Tapering From Long-term Opioid Therapy in Chronic Pain Population. Randomized Controlled Trial With 12 Months Follow up N/A
Recruiting NCT05790551 - Suboxone Dispenser for OUD N/A
Completed NCT03174067 - Buprenorphine in the Emergency Department Phase 4
Completed NCT04731935 - Novel Earpiece for Transcutaneous Auricular Neurostimulation (tAN) for Symptoms of Opioid Withdrawal N/A
Completed NCT04470050 - Dexmedetomidine in the Treatment of Symptoms Of Acute Opioid Withdrawal Phase 1/Phase 2
Not yet recruiting NCT06442566 - ACTION: Trial of Adding Buprenorphine, CBT, and TMS to Improve Outcomes of Long-Term Opioid Therapy for Chronic Pain Phase 1/Phase 2
Recruiting NCT05307458 - Evaluating the Pharmacokinetics and Patient Outcomes of Buprenorphine Microdosing
Completed NCT03789214 - Medical Management of Sleep Disturbance During Opioid Tapering Phase 2
Recruiting NCT04759703 - Treatment of Restless Legs Symptoms With Pramipexole to Improve the Outcomes of Protracted Opioid Withdrawal in OUD Phase 2/Phase 3

External Links